Valuation: NetraMark Holdings Inc.

Capitalization 94.81M 68.39M 58.79M 55.07M 51.33M 6.16B 103M 644M 249M 2.91B 257M 251M 10.63B P/E ratio 2025 *
-
P/E ratio 2026 * -
Enterprise value 94.81M 68.39M 58.79M 55.07M 51.33M 6.16B 103M 644M 249M 2.91B 257M 251M 10.63B EV / Sales 2025 *
152x
EV / Sales 2026 * -
Free-Float
9.54%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-0.93%
1 week-7.83%
Current month-5.36%
1 month-13.11%
3 months-32.91%
6 months-23.74%
Current year+6.00%
More quotes
1 week 0.97
Extreme 0.97
1.15
1 month 0.94
Extreme 0.94
1.29
Current year 0.79
Extreme 0.79
1.8
1 year 0.79
Extreme 0.79
1.8
3 years 0.15
Extreme 0.15
1.8
5 years 0.15
Extreme 0.15
3.17
10 years 0.15
Extreme 0.15
3.17
More quotes
Manager TitleAgeSince
Chief Executive Officer - 16/02/2022
Director of Finance/CFO 56 17/07/2022
Chief Tech/Sci/R&D Officer - 11/08/2025
Director TitleAgeSince
Chairman 39 08/06/2025
Director/Board Member - -
Director/Board Member - 15/06/2022
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-0.93%-7.83%+37.66%+583.87% 67.99M
+0.48%-0.48%+10.46%+89.46% 3,574B
+2.16%+9.65%+160.21%+2,272.85% 424B
+0.07%+10.18%+4.00%+95.75% 91.81B
+0.65%+13.93%-20.62%+34.06% 88.38B
-1.02%+2.86%+145.20%+1,953.03% 81.64B
-1.05%-0.20%+14.12%+118.30% 80.17B
+1.12%+3.83%+76.53%+183.26% 66.83B
+0.15%+1.74%+31.71%+127.91% 45.73B
+1.78%+7.63%-44.58%+13.00% 41.19B
Average +0.20%+3.30%+41.47%+547.15% 449.37B
Weighted average by Cap. -0.10%+0.51%+27.05%+330.01%
See all sector performances

Financials

2025 *2026 *
Net sales 622K 449K 386K 361K 337K 40.39M 677K 4.23M 1.63M 19.08M 1.68M 1.65M 69.76M -
Net income - -
Net Debt - -
More financial data * Estimated data
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-
More about the company
Date Price Change Volume
05/12/25 1.060 $ -0.93% 68,201
04/12/25 1.070 $ +10.31% 50,500
03/12/25 0.9700 $ -7.62% 31,010
02/12/25 1.050 $ -4.55% 6,200
01/12/25 1.100 $ -1.79% 11,004

Delayed Quote Canadian Securities Exchange, December 05, 2025 at 08:49 pm

More quotes

Quarterly revenue - Rate of surprise